Bioterrorism and its aftermath.
Navepegritide NDA submitted to treat children with achondroplasia
Submission is based on 3 clinical trials, including data from the ApproaCH Trial among children with achondroplasia.
Food Insecurity and the Dangers of Infant Formula Dilution
Weekly review: Multiple FDA approvals, expert discussions and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Demystifying Infant Formula
5 pediatric FDA decisions to watch for in Q2 2025
A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.
Remestemcel-L now available to treat steroid-refractory acute graft-versus-host disease
Mesoblast's remestemcel-L (Ryoncil) was approved by the FDA on December 18, 2024 to treat SR-aGVHD in patients 2 months and older. Now, it is available for purchase.
